Get the Stockscreener App
107.42
1.10%
-1.19
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $107.42, with a volume of 21.77M.
It is down -1.10% in the last 24 hours and down -13.75% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$108.61
Open:
$108.27
24h Volume:
21.77M
Relative Volume:
3.13
Market Cap:
$186.79B
Revenue:
$44.33B
Net Income/Loss:
$6.48B
P/E Ratio:
29.01
EPS:
3.7033
Net Cash Flow:
$6.92B
1W Performance:
-11.78%
1M Performance:
-13.75%
6M Performance:
-14.63%
1Y Performance:
-12.82%
1-Day Range:
$106.08
$110.05
1-Week Range:
$105.78
$122.49
52-Week Range:
$105.78
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
107.42 | 188.86B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
92.51 | 135.38B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.04 | 137.16B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.88 | 129.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.66 | 49.00B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Is Abbott's January pullback a good time to buy? - MSN
Mn Services Vermogensbeheer B.V. Acquires 9,900 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Resona Asset Management Co. Ltd. - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
UniSuper Management Pty Ltd Buys 44,239 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Gibbs Wealth Management - MarketBeat
Abbott Laboratories (ABT) Margin Compression Challenges Steady Compounder Narrative After FY 2025 Results - simplywall.st
Earnings snapshot: Abbott Laboratories Q4 beats profit estimates, but misses on revenue; initiates Q1 and FY26 outlook - MSN
Assessing Abbott Laboratories (ABT) Valuation After Q4 2025 Earnings Miss And Softer 2026 Guidance - Yahoo Finance
Citigroup Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00 - MarketBeat
Abbott India Under Scrutiny Due To Cough Syrup Supply ChainAbbott Laboratories (NYSE:ABT) - Benzinga
Tesla To $360? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Sanford C. Bernstein Lowers Abbott Laboratories (NYSE:ABT) Price Target to $125.00 - MarketBeat
UBS reiterates Buy rating on Abbott Labs stock with $158 price target - Investing.com
Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2 - Benzinga
Abbott Faces Near-Term Headwinds in Nutrition and Slower Long-Term Libre Growth - Morningstar
Abbott Laboratories (NYSE:ABT) Given New $130.00 Price Target at Raymond James Financial - MarketBeat
Abbott Laboratories (NYSE:ABT) Price Target Cut to $132.00 by Analysts at Oppenheimer - MarketBeat
The Goldman Sachs Group Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott Laboratories (NYSE:ABT) Price Target Lowered to $135.00 at Royal Bank Of Canada - MarketBeat
Oppenheimer Adjusts Price Target for Abbott Laboratories (ABT) | - GuruFocus
2 Healthcare Names That Could Get a Big Boost From Earnings - Investing.com
Abbott Labs stock price target lowered to $125 by Bernstein SocGen - Investing.com
Evercore ISI Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Is The Fall In Abbott Stock Justified? - Forbes
Piper Sandler Lowers Price Target for Abbott Laboratories (ABT) - GuruFocus
Abbott Labs stock price target lowered to $135 by RBC Capital By Investing.com - Investing.com Nigeria
TD Cowen lowers Abbott Labs stock price target on Q4 revenue miss - Investing.com
Piper Sandler lowers Abbott Labs stock price target on nutrition segment weakness By Investing.com - Investing.com South Africa
Teacher Retirement System of Texas Sells 122,066 Shares of Abbott Laboratories $ABT - MarketBeat
How Did Abbott Fare In Q4 And What Lies Ahead? - Trefis
Piper Sandler Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Benchmark reiterates Buy rating on Abbott Labs stock amid tepid Q4 - Investing.com
Abbott Labs stock price target lowered to $135 by RBC Capital - Investing.com
Abbott faces India scrutiny in cough syrup abuse investigation, documents show - Reuters
Abbott Laboratories (NYSE:ABT) Q4 2025 earnings call transcript - MSN
Piper Sandler lowers Abbott Labs stock price target on nutrition segment weakness - Investing.com
Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript - Insider Monkey
Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings - Fierce Biotech
Abbott Labs stock price target lowered to $122 by Wells Fargo on nutrition headwinds - Investing.com
Abbott Laboratories: Buy This Dividend King On Sale Now (NYSE:ABT) - Seeking Alpha
Abbott Labs stock price target lowered to $132 at Oppenheimer on Q4 results - Investing.com Australia
Abbott Labs stock price target lowered to $145 by Jefferies on nutrition segment miss - Investing.com Nigeria
Strs Ohio Sells 35,951 Shares of Abbott Laboratories $ABT - MarketBeat
Simplicity Wealth LLC Has $2.22 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Labs stock price target lowered to $130 by Raymond James - Investing.com
Abbott stock sank 10% on earnings — what traders watch before the bell - TechStock²
Abbott Labs (ABT) Stock Tumbles 8% as Weak Nutrition Sales Offset Strong Device Growth - CoinCentral
Abbott Stock Suffers Worst Drop In More Than 20 Years - Eudaimonia and Co
Abbott Laboratories Share Price Falls 8% After Revenue Miss | Stock Market Today - Samco
ABT Q4 Deep Dive: Nutrition Weakness and Innovation Shape 2026 Outlook - FinancialContent
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.34%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):